Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR, NMPA) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

Clinical Trial

Self-administered tDCS for Improving Single- and Dual-task Gait in Patients With PD

NCT: NCT06324448 · COMPLETED

NCT IDNCT06324448
StatusCOMPLETED
Start Date2024-02-15
Completion2026-02-24

Brief Summary

The purpose of this study is to investigate the efficacy and safety of self-administered transcranial direct current stimulation to improve the single- and dual-task gait in patients with Parkinson's disease.

Frequently Asked Questions

What is Self-administered tDCS for Improving Single- and Dual-task Gait in Patients With PD?

Self-administered tDCS for Improving Single- and Dual-task Gait in Patients With PD is a clinical trial registered under NCT06324448. Current status: COMPLETED.

What is the status of NCT06324448?

The current status of NCT06324448 (Self-administered tDCS for Improving Single- and Dual-task Gait in Patients With PD) is: COMPLETED.

When did Self-administered tDCS for Improving Single- and Dual-task Gait in Patients With PD start?

Self-administered tDCS for Improving Single- and Dual-task Gait in Patients With PD started on 2024-02-15.

Official Source

View on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.

↑